Base de dados : MEDLINE
Pesquisa : C23.888.942.343.550 [Categoria DeCS]
Referências encontradas : 611 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 62 ir para página                         

  1 / 611 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28799582
[Au] Autor:Hodgkinson L
[Ad] Endereço:Clarivate Analytics, London, UK. lisa.hodgkinson@clarivate.com.
[Ti] Título:American Urological Association (AUA) - 112th Annual Meeting (May 12-16, 2017 - Boston, Massachusetts, USA).
[So] Source:Drugs Today (Barc);53(6):367-369, 2017 Jun.
[Is] ISSN:1699-3993
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:The American Urological Association (AUA) stands at the forefront of technology development and urological education for urologists and urological healthcare professionals worldwide. The 112th annual meeting brought together a wide range of researchers in the field of urology to access knowledge, up-to-date clinical guidelines and advances in research. The meeting consisted of plenary and moderated poster, podium and video sessions highlighting the latest research and advances in urological medicine. This report highlights some of the presentations on therapeutic developments for a range of urological conditions.
[Mh] Termos MeSH primário: Urologia/organização & administração
[Mh] Termos MeSH secundário: Acetanilidas/administração & dosagem
Administração Intranasal
Idoso
Idoso de 80 Anos ou mais
Antibióticos Antineoplásicos/administração & dosagem
Antibióticos Antineoplásicos/uso terapêutico
Carcinoma de Células de Transição/tratamento farmacológico
Ensaios Clínicos Fase III como Assunto
Desamino Arginina Vasopressina/administração & dosagem
Desamino Arginina Vasopressina/uso terapêutico
Preparações de Ação Retardada
Método Duplo-Cego
Combinação de Medicamentos
Seres Humanos
Hidrogéis
Mitomicina/administração & dosagem
Mitomicina/uso terapêutico
Estudos Multicêntricos como Assunto
Noctúria/tratamento farmacológico
Ensaios Clínicos Controlados Aleatórios como Assunto
Succinato de Solifenacina/administração & dosagem
Tiazóis/administração & dosagem
Estados Unidos
Neoplasias da Bexiga Urinária/tratamento farmacológico
Bexiga Urinária Hiperativa/tratamento farmacológico
[Pt] Tipo de publicação:CONGRESSES
[Nm] Nome de substância:
0 (Acetanilides); 0 (Antibiotics, Antineoplastic); 0 (Delayed-Action Preparations); 0 (Drug Combinations); 0 (Hydrogels); 0 (Thiazoles); 50SG953SK6 (Mitomycin); ENR1LLB0FP (Deamino Arginine Vasopressin); KKA5DLD701 (Solifenacin Succinate); MVR3JL3B2V (mirabegron)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE
[do] DOI:10.1358/dot.2017.53.6.2662981


  2 / 611 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28444710
[Au] Autor:Vahabi B; Wagg AS; Rosier PFWM; Rademakers KLJ; Denys MA; Pontari M; Lovick T; Valentini FA; Nelson PP; Andersson KE; Fry CH
[Ad] Endereço:Department of Biological, Biomedical and Analytical Sciences, University of the West of England, Bristol, United Kingdom.
[Ti] Título:Can we define and characterize the aging lower urinary tract?-ICI-RS 2015.
[So] Source:Neurourol Urodyn;36(4):854-858, 2017 04.
[Is] ISSN:1520-6777
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The prevalence of lower urinary tract (LUT) symptoms increases with age but the etiology is unknown. This article aims to identify research directions that clarify the basis of this association. The initial question is whether biological age is the variable of interest or a time-dependent accumulation of factors that impact on LUT function at rates that differ between individuals. In particular, the accumulation of conditions or agents due to inflammatory states or tissue ischemia is important. Much of the above has been concerned with changes to bladder function and morphology. However, the outflow tract function is also affected, in particular changes to the function of external sphincter skeletal muscle and associated sacral motor nerve control. Nocturia is a cardinal symptom of LUT dysfunction and is more prevalent with aging. Urine production is determined by diurnal changes to the production of certain hormones as well as arterial blood pressure and such diurnal rhythms are blunted in subjects with nocturia, but the causal links remain to be elucidated. Changes to the central nervous control of LUT function with age are also increasingly recognized, whether in mid-brain/brainstem regions that directly affect LUT function or in higher centers that determine psycho-social and emotional factors impinging on the LUT. In particular, the linkage between increasing white matter hyperintensities and LUT dysfunction during aging is recognized but not understood. Overall, a more rational approach is being developed to link LUT dysfunction with factors that accumulate with age, however, the precise causal pathways remain to be characterized. Neurourol. Urodynam. 36:854-858, 2017. © 2017 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Envelhecimento/fisiologia
Sintomas do Trato Urinário Inferior/fisiopatologia
Sistema Urinário/fisiopatologia
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Sintomas do Trato Urinário Inferior/etiologia
Modelos Biológicos
Noctúria/fisiopatologia
Doenças da Bexiga Urinária/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1002/nau.23035


  3 / 611 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28414539
[Au] Autor:Andrews J
[Ad] Endereço:Director, Sedaca.
[Ti] Título:Sleep and dementia.
[So] Source:Br J Community Nurs;22(4):197-198, 2017 Apr 02.
[Is] ISSN:1462-4753
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Cuidadores
Enfermagem em Saúde Comunitária
Demência/enfermagem
Higiene do Sono
Transtornos do Sono-Vigília/enfermagem
[Mh] Termos MeSH secundário: Agressão
Seres Humanos
Vida Independente
Noctúria/enfermagem
Enurese Noturna/enfermagem
Distribuição Espacial da População
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170615
[Lr] Data última revisão:
170615
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170418
[St] Status:MEDLINE
[do] DOI:10.12968/bjcn.2017.22.4.197


  4 / 611 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28394492
[Au] Autor:Park YH; Kim TH; Lee SW; Chung BH; Cho JS; Lee JY
[Ad] Endereço:Department of Urology, College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.
[Ti] Título:Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms.
[So] Source:Low Urin Tract Symptoms;9(2):75-81, 2017 May.
[Is] ISSN:1757-5672
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: We aimed to examine the treatment patterns, and patient-reported outcomes (PROs) in benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms. METHODS: Seven hundred and forty seven patients were included in this prospective observational study. The primary endpoint was to describe the medical treatment patterns for BPH patients with OAB symptoms. The secondary endpoint was to determine the PROs of these patients. Clinical outcome was assessed using International prostate symptom score (IPSS), and PROs were measured using BPH-Related QoL Questionnaire Korea 1 (BPH QoL K1) and Euroqol-5 Dimension (EQ-5D). RESULTS: When starting the study, 391 patients (52.3%) received α-blocker monotherapy, whereas 356 (47.7%) received combination therapy with anticholinergics. Of the 369 patients who completed the 6-month treatment, 139 patients (37.7%) still received α-blocker monotherapy, 122 (33.1%) still received combination therapy with anticholinergics, and 108 (29.3%) received subsequent anticholinergics in addition to α-blocker. When the patients were stratified, storage subscore was higher (9.5 vs. 8.8, P = 0.034) and voiding subscore (9.7 vs. 11.6, P = 0.001) was lower in patients with anticholinergics than those without it. Although all treatment groups reported a significant improvement from baseline, no significant between-group differences in changes in IPSS, EQ-5D and BPH QoL K1 was found. CONCLUSIONS: About one-third of patients received α-blocker monotherapy, one-third received combination therapy with anticholinergics, and another one-third received subsequent anticholinergics in addition to α-blocker. Storage subscore was higher in patients with anticholinergics than those without it, but vice-versa for voiding subscore. Similar improvement on clinical outcomes and PROs was observed in all treatment groups.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos alfa/uso terapêutico
Antagonistas Colinérgicos/uso terapêutico
Hiperplasia Prostática/tratamento farmacológico
Bexiga Urinária Hiperativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Análise de Variância
Quimioterapia Combinada
Seres Humanos
Masculino
Meia-Idade
Noctúria/tratamento farmacológico
Noctúria/fisiopatologia
Medidas de Resultados Relatados pelo Paciente
Estudos Prospectivos
Hiperplasia Prostática/fisiopatologia
Inquéritos e Questionários
Resultado do Tratamento
Bexiga Urinária Hiperativa/fisiopatologia
Micção/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Cholinergic Antagonists)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170411
[St] Status:MEDLINE
[do] DOI:10.1111/luts.12112


  5 / 611 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28384655
[Au] Autor:Fralick M; Kesselheim AS
[Ad] Endereço:Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts2University of Toronto Clinician-Scientist Program, Toronto, Ontario, Canada.
[Ti] Título:FDA Approval of Desmopressin for Nocturia.
[So] Source:JAMA;317(20):2059-2060, 2017 05 23.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Desamino Arginina Vasopressina/uso terapêutico
Aprovação de Drogas
Noctúria/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração por Inalação
Adulto
Comitês Consultivos
Criança
Desamino Arginina Vasopressina/efeitos adversos
Seres Humanos
Hiponatremia/induzido quimicamente
Noctúria/etiologia
Vigilância de Produtos Comercializados
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
ENR1LLB0FP (Deamino Arginine Vasopressin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170407
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.4316


  6 / 611 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28364461
[Au] Autor:Krystal AD; Preud'homme XA
[Ad] Endereço:Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC.
[Ti] Título:Double-Blind, Placebo-Controlled, Crossover Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia.
[So] Source:Sleep;40(1), 2017 Jan 01.
[Is] ISSN:1550-9109
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Study Objectives: Nocturia, voids which disturb sleep, is the most common cause of awakenings and is associated with daytime sleepiness. Because the standard treatments for the most common causes of nocturia are relatively ineffective, many treated patients with nocturia are left with residual sleepiness. We carried out this pilot study to evaluate the potential of armodafinil to be an effective means of addressing the sleepiness that persists in many nocturia patients, despite their receiving standard therapy. Methods: This was a double-blind, placebo-controlled, crossover study carried out in 28 patients with nocturia who were receiving standard clinical therapy for their nocturia and who had an Epworth Sleepiness Scale (ESS) score of at least 10. Subjects received 4 weeks of both armodafinil (150-250 mg) and placebo with order randomized. Results: Armodafinil led to statistically significant improvement in sleepiness compared to placebo as indicated by the ESS (the primary outcome; p < .002) as well as the Clinical Global Impression of Improvement in Sleepiness scale (key secondary outcome; p = .01). Armodafinil did not increase nocturic events or significantly increase adverse effects versus placebo. Conclusions: This pilot study, the first double-blind, placebo-controlled trial assessing whether a wake-promoting therapy can improve residual daytime sleepiness in patients with treated nocturia, indicates the promise of armodafinil for addressing this residual sleepiness and provides impetus to carry out a large-scale study to definitively evaluate whether armodafinil is an effective therapy for the many patients with nocturia who experience daytime sleepiness that persists, despite their receiving standard therapy for this condition.
[Mh] Termos MeSH primário: Compostos Benzidrílicos/farmacologia
Compostos Benzidrílicos/uso terapêutico
Fadiga/complicações
Fadiga/tratamento farmacológico
Noctúria/complicações
Noctúria/terapia
Fases do Sono/efeitos dos fármacos
[Mh] Termos MeSH secundário: Estudos Cross-Over
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Distribuição Aleatória
Resultado do Tratamento
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzhydryl Compounds); V63XWA605I (armodafinil)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171011
[Lr] Data última revisão:
171011
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170402
[St] Status:MEDLINE
[do] DOI:10.1093/sleep/zsw020


  7 / 611 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28347292
[Au] Autor:Delgado D; Canham L; Cotterill N; Cottrell D; Drake MJ; Inglis K; Owen D; White P
[Ad] Endereço:Bristol Urological Institute, North Bristol NHS Trust, Southmead Hospital, Bristol, BS10 5NB, UK.
[Ti] Título:Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS).
[So] Source:BMC Neurol;17(1):63, 2017 Mar 27.
[Is] ISSN:1471-2377
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Nocturia (the symptom of needing to wake up to pass urine) is common in progressive Multiple Sclerosis (MS) patients. Moderate-to-severe nocturia affects quality of life, can exacerbate fatigue and may affect capacity to carry out daily activities. Melatonin is a natural hormone regulating circadian cycles, released by the pineal gland at night-time, and secretion is impaired in MS. Melatonin levels can be supplemented by administration in tablet form at bedtime. The aim of this study is to evaluate the effect of melatonin on mean number of nocturia episodes per night in MS patients. Secondary outcome measures will assess impact upon quality of life, urinated volumes, lower urinary tract symptoms (LUTS), cognition, sleep quality and sleep disturbance of partners. METHODS: A randomized, double blind, placebo controlled, crossover trial consisting of two, six week treatment phases (active drug melatonin 2 mg or placebo), with a 1 month wash-out period in between. The primary outcome (change in nocturia episodes per night) in this two arm, two treatment, two period crossover design, will be objectively measured using frequency volume charts (FVC) at baseline and following both treatment phases. Questionnaires will be used to assess quality of life, sleep quality, safety and urinary tract symptoms. Qualitative interviews of participants and partners will explore issues including quality of life, mechanisms of sleep disturbance and impact of nocturia on partners. DISCUSSION: This study will evaluate whether melatonin reduces the frequency of nocturia episodes in MS patients, and therefore whether 'Circadin' has the potential to reduce LUTS and fatigue, and improve cognition and overall quality of life. TRIAL REGISTRATION: (EudraCT reference) 2012-00418321 registered: 25/01/13. ISRCTN Registry: ISRCTN38687869.
[Mh] Termos MeSH primário: Depressores do Sistema Nervoso Central/farmacologia
Protocolos Clínicos
Melatonina/farmacologia
Esclerose Múltipla/complicações
Noctúria/tratamento farmacológico
Avaliação de Resultados (Cuidados de Saúde)
[Mh] Termos MeSH secundário: Adulto
Depressores do Sistema Nervoso Central/administração & dosagem
Estudos Cross-Over
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Melatonina/administração & dosagem
Meia-Idade
Noctúria/etiologia
Qualidade de Vida
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Central Nervous System Depressants); JL5DK93RCL (Melatonin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170529
[Lr] Data última revisão:
170529
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170329
[St] Status:MEDLINE
[do] DOI:10.1186/s12883-017-0845-y


  8 / 611 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28279978
[Ti] Título:Desmopressin for nocturia in adults.
[So] Source:Drug Ther Bull;55(3):30-32, 2017 Mar.
[Is] ISSN:1755-5248
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Desmopressin has been used for many years in the treatment of diabetes insipidus, nocturnal enuresis (involuntary urination while asleep) and nocturia associated with multiple sclerosis (in adults aged up to 65 years); it has also been recommended in certain circumstances for the treatment of nocturia in men and women (previously, an unlicensed use). Recently, a new brand of desmopressin sublingual tablet (lyophilisate-an orally disintegrating tablet; Noqdirna-Ferring) has been licensed for use in adults of any age for the treatment of nocturia due to idiopathic nocturnal polyuria. The tablets contain a lower dose of desmopressin than was previously available. Unusually, there are different recommended doses for men and women. In this article, we consider the evidence on desmopressin in the treatment of idiopathic nocturnal polyuria in adults, and how this new formulation fits with current management strategies.
[Mh] Termos MeSH primário: Desamino Arginina Vasopressina/uso terapêutico
Noctúria/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Sublingual
Adulto
Idoso
Desamino Arginina Vasopressina/administração & dosagem
Desamino Arginina Vasopressina/efeitos adversos
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Masculino
Meia-Idade
Noctúria/complicações
Poliúria/complicações
Poliúria/tratamento farmacológico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
ENR1LLB0FP (Deamino Arginine Vasopressin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170626
[Lr] Data última revisão:
170626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE
[do] DOI:10.1136/dtb.2017.3.0460


  9 / 611 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28129482
[Au] Autor:Obayashi K; Saeki K; Negoro H; Kurumatani N
[Ad] Endereço:Department of Community Health and Epidemiology, Nara Medical University School of Medicine, Nara, Japan.
[Ti] Título:Nocturia increases the incidence of depressive symptoms: a longitudinal study of the HEIJO-KYO cohort.
[So] Source:BJU Int;120(2):280-285, 2017 Aug.
[Is] ISSN:1464-410X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate the association between nocturia and the incidence of depressive symptoms. PARTICIPANTS AND METHODS: Of 1 127 participants in the HEIJO-KYO population-based cohort, 866 elderly individuals (mean age 71.5 years) without depressive symptoms at baseline were followed for a median period of 23 months. Nocturnal voiding frequency was logged using a standardized urination diary and nocturia was defined as a frequency of ≥2 voids per night. Depressive symptoms were assessed using the Geriatric Depression Scale. RESULTS: During the follow-up period, 75 participants reported the development of depressive symptoms (score ≥6). The nocturia group (n = 239) exhibited a significantly higher hazard ratio (HR) for incident depressive symptoms than the non-nocturia group (n = 627) in the Cox proportional hazard model, which was adjusted for age, gender, alcohol consumption, day length and presence of hypertension and chronic kidney disease (HR 1.69, 95% confidence interval [CI] 1.05-2.72; P = 0.032]. The significance remained after adjustment for sleep disturbances (HR 1.68, 95% CI 1.02-2.75; P = 0.040). Analysis stratified by gender showed that the association between nocturia and the incidence of depressive symptoms was significant in men (HR 2.51, 95% CI 1.27-4.97; P = 0.008) but not in women (HR 1.12, 95% CI 0.53-2.44; P = 0.74). CONCLUSIONS: Nocturia is significantly associated with a higher incidence of depressive symptoms in the general elderly population, and gender differences may underlie this association.
[Mh] Termos MeSH primário: Depressão/epidemiologia
Noctúria/psicologia
[Mh] Termos MeSH secundário: Idoso
Comorbidade
Feminino
Seres Humanos
Incidência
Masculino
Modelos de Riscos Proporcionais
Fatores de Risco
Fatores Sexuais
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170728
[Lr] Data última revisão:
170728
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170128
[St] Status:MEDLINE
[do] DOI:10.1111/bju.13791


  10 / 611 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28104161
[Au] Autor:Mitsui T; Morita K; Iwami D; Kitta T; Kanno Y; Moriya K; Takeda M; Shinohara N
[Ad] Endereço:Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Hokkaido, Japan; Department of Urology, University of Yamanashi Graduate School of Medical Science, Yamanashi, Japan. Electronic address: tmitsui@yamanashi.ac.jp.
[Ti] Título:Does the Age of Donor Kidneys Affect Nocturnal Polyuria in Patients With Successful Real Transplantation?
[So] Source:Transplant Proc;49(1):65-67, 2017 Jan - Feb.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We investigated whether the age of donor kidneys influences the incidence of nocturnal polyuria in patients with successful renal transplantation (RTX). METHODS: Eighty-five patients (45 men and 40 women) undergoing RTX (median age, 47 years) were included in this study. Twenty-four-hour bladder diaries were kept for 3 days, and nocturnal polyuria was defined as a nocturnal polyuria index (nocturnal urine volume/24-hour urine volume) of >0.33. Risk factors for nocturnal polyuria were analyzed in patients with RTX by means of the Mann-Whitney U test, χ test, and a logistic regression analysis. RESULTS: End-stage renal disease (ESRD) developed from diabetes mellitus in 16 patients (19%). Sixty-five patients (76%) received pre-transplant dialysis, with a median duration of 5 years. The median serum creatinine level and body mass index at the most recent visit were 1.2 mg/dL and 21.2 kg/m , respectively. On the basis of the 24-hour bladder diaries, nocturnal polyuria was identified in 48 patients (56%). A logistic regression analysis revealed that diabetes mellitus as the original disease for ESRD was the only risk factor for nocturnal polyuria (odds ratio, 8.95; 95% confidence interval, 2.01-65.3; P = .0028). The age of donor kidneys at examination did not affect the incidence of nocturnal polyuria (P = .9402). CONCLUSIONS: Nocturnal polyuria was not uncommon in patients with successful RTX. Diabetes mellitus as the original disease for ESRD was the only risk factor for nocturnal polyuria, whereas the age of donor kidneys at examination did not affect the incidence of nocturnal polyuria. Thus, nocturnal polyuria is caused by recipient factors but not donor factors.
[Mh] Termos MeSH primário: Fatores Etários
Transplante de Rim/efeitos adversos
Noctúria/epidemiologia
Poliúria/epidemiologia
Doadores de Tecidos
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Incidência
Masculino
Meia-Idade
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170121
[St] Status:MEDLINE



página 1 de 62 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde